131 related articles for article (PubMed ID: 25185088)
1. Reply to F. Tomao et al.
Pujade-Lauraine E; Hilpert F; Poveda A
J Clin Oncol; 2014 Nov; 32(31):3580. PubMed ID: 25185088
[No Abstract] [Full Text] [Related]
2. Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer.
Liu JF; Cannistra SA
J Clin Oncol; 2014 May; 32(13):1287-9. PubMed ID: 24637996
[No Abstract] [Full Text] [Related]
3. Combination of bevacizumab and chemotherapy for platinum-resistant recurrent ovarian cancer: some observations about the AURELIA trial.
Tomao F; Tomao S; Benedetti Panici P
J Clin Oncol; 2014 Nov; 32(31):3580. PubMed ID: 25185105
[No Abstract] [Full Text] [Related]
4. Discussion: session 1.
Sehouli J; del Campo JM; Lorusso D
Future Oncol; 2013 Dec; 9(12 Suppl):25-7. PubMed ID: 24195527
[No Abstract] [Full Text] [Related]
5. [Standard of chemotherapy in ovarian cancer].
Pfleiderer A; Meerpohl HG
Chirurg; 1994 Jan; 65(1):18-22. PubMed ID: 8149794
[No Abstract] [Full Text] [Related]
6. Treatment of recurrent ovarian cancer: increasing options--"recurrent" results.
Ozols RF
J Clin Oncol; 1997 Jun; 15(6):2177-80. PubMed ID: 9196128
[No Abstract] [Full Text] [Related]
7. Chemotherapy of ovarian cancer.
Ozols RF; Young RC
Semin Oncol; 1991 Jun; 18(3):222-32. PubMed ID: 2042062
[No Abstract] [Full Text] [Related]
8. [Chemotherapy of a second instance of carcinoma of the ovary].
Giaccone G; Clerico M; Donadio M; Calciati A
Minerva Ginecol; 1984 Apr; 36(4):209-12. PubMed ID: 6462524
[No Abstract] [Full Text] [Related]
9. ICON-6: the danger of changing study design midstream.
Norrie J
Lancet; 2016 Mar; 387(10023):1031-1032. PubMed ID: 27025174
[No Abstract] [Full Text] [Related]
10. A unique role for retrospective studies in clinical oncology.
Markman M
Oncology; 2014; 86(5-6):350. PubMed ID: 24942408
[No Abstract] [Full Text] [Related]
11. Does intraperitoneal therapy have a role in recurrent ovarian cancer?
Cain JM
World J Surg; 2007 Sep; 31(9):1821. PubMed ID: 17623233
[No Abstract] [Full Text] [Related]
12. Early versus delayed treatment of relapsed ovarian cancer.
Rustin G; van der Burg M; Griffin C; Qian W; Swart AM
Lancet; 2011 Jan; 377(9763):380-1. PubMed ID: 21277438
[No Abstract] [Full Text] [Related]
13. [Does nothing else work after cisplatin in ovarian carcinoma?].
Krafft W
Zentralbl Gynakol; 1990; 112(21):1321-3. PubMed ID: 2278214
[No Abstract] [Full Text] [Related]
14. Treatment by combined chemotherapy for recurrent ovarian cancer.
Shershah S
J Pak Med Assoc; 1985 Nov; 35(11):341-3. PubMed ID: 3935821
[No Abstract] [Full Text] [Related]
15. Clinical trials referral resource. Clinical trials in ovarian cancer, Part 2.
Trimble EL; Schoenfeldt M; Cornelison TL; Wright J; Kolker A; Christian M
Oncology (Williston Park); 2002 Dec; 16(12):1660-2, 1665-7. PubMed ID: 12520641
[No Abstract] [Full Text] [Related]
16. Gynaecological cancer: AURELIA--ovarian combination.
Errico A
Nat Rev Clin Oncol; 2014 May; 11(5):242. PubMed ID: 24687034
[No Abstract] [Full Text] [Related]
17. [Comparison of pegylated liposomal doxorubicin and carboplatin with paclitaxel and carboplatin in the treatment of patients with late recurrence of platin-sensitive ovarian carcinoma].
Zvaríková M
Klin Onkol; 2011; 24(6):475-6. PubMed ID: 22268244
[No Abstract] [Full Text] [Related]
18. Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?
Markman M
Gynecol Oncol; 2001 Apr; 81(1):1-2. PubMed ID: 11277641
[No Abstract] [Full Text] [Related]
19. "Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma".
Piver MS
Cancer Treat Rep; 1986 Dec; 70(12):1466. PubMed ID: 3791262
[No Abstract] [Full Text] [Related]
20. Management of recurrent endodermal sinus tumor of the ovary associated with pregnancy.
Tao T; Yang JX; Cao DY; Liu JT; Shen K
Gynecol Oncol; 2011 Aug; 122(2):455-6. PubMed ID: 21600636
[No Abstract] [Full Text] [Related]
[Next] [New Search]
